AbbVie just slashed its 2026 profit forecast by 14 cents per share due to its big Apogee Therapeutics acquisition — a strategic move to bolster treatments for eczema and asthma. While the market reacted with a dip, the company actually beat Q2 earnings, driven by strong sales of immunology drugs Skyrizi and Rinvoq — even as Humira’s decline continues. With Humira facing generic competition, AbbVie’s aggressive acquisitions, like the depression drug from Gilgamesh, signal a push to future-proof its pipeline. It’s a high-wire act: balancing current wins with bold bets on tomorrow’s blockbusters.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
